Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine. Dr. Diaz formally assumes the role as David Spriggs, MD, steps down after nearly 13 years.
Jae Park, MD, a hematologic oncologist and assistant attending physician at MSK, will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American Association for Cancer Research (AACR) Annual Meeting. This research has been selected to be featured in the meeting’s press program.
Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the oldest and largest professional organization dedicated to advancing cancer research, and the press program highlights cancer research that a panel of AACR experts considers the most significant of the year and deserving of media attention.
Jeffrey A. Drebin, MD, PhD, has been named the new Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Drebin brings to MSK decades of experience as a world-class surgical oncologist specializing in pancreaticobiliary, upper gastrointestinal and liver surgery. He joins MSK from the Perelman School of Medicine of the University of Pennsylvania (UPenn) where he was most recently the John Rhea Barton Professor and Chairman of the Department of Surgery. Dr. Drebin formally assumes his new role as Peter Scardino, MD, steps down as Chairman after ten years of visionary leadership.
MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.
Today, after a yearlong review and collaborative process, Miami Cancer Institute at Baptist Health South Florida became a full member of the Memorial Sloan Kettering (MSK) Cancer Alliance. Miami Cancer Institute is the third member of the MSK Cancer Alliance, a transformative initiative that aims to improve the quality of care and outcomes for people with cancer in community settings.
Memorial Sloan Kettering and Hackensack Meridian Health announced the Memorial Sloan Kettering–Hackensack Meridian Health partnership, a joint venture that will combine both organizations’ unparalleled expertise in all areas of cancer care and research to accelerate new discoveries and improve the lives of patients they jointly serve.
Nearly 20 years have passed since Memorial Sloan Kettering Cancer Center (MSK) first opened its doors in the Garden State. Since then, an explosion of knowledge and data has resulted in far better outcomes for thousands of people with cancer, including many who’ve sought care at MSK’s facility in New Jersey.
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.